Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective evaluation of continuation therapy with midostaurin in adult patients with CBF-acute myeloid leukemia
2017-002094-18Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in core binding factor acute myeloid leukemia, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: 2-year relapse incidence. Started Jun 2021; status: completed.
02
Drugs
midostaurin
03
Conditions
core binding factor acute myeloid leukemia
Beyond the preview
Go deeper on 2017-002094-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002094-18.